Recent advances in the treatment of erectile dysfunction in patients with diabetes mellitus

Endocrine Practice

Volumn 9, Issue 1, 2003, Pages 52-63

  Koppiker, Nandan ^a   Boolell, Mitradev ^a   Price, David ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b MORRISTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALDOSE REDUCTASE INHIBITOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA INTERMEDIN; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ENDOTHELIN 1; GAP JUNCTION PROTEIN; IMMUNOPHILIN; INSULIN; MOXISYLYTE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROTRANSMITTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E1; SILDENAFIL; SULFONYLUREA DERIVATIVE; TACROLIMUS; TRAZODONE; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE; YOHIMBINE;

DIABETES MELLITUS; DISEASE ASSOCIATION; DYSPEPSIA; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; MALE; NAUSEA AND VOMITING; PAIN; PATHOGENESIS; PENILE BLOOD FLOW; PENILE FIBROSIS; PRIAPISM; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; VISUAL DISORDER;

EID: 0037821696     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.9.1.52     Document Type: Review

References (111)

1. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
2. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Ann Rev Pharmacol Toxicol. 1990;30:535-560.
3. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
4. Saenz de Tejada I, Blanco R, Goldstein I, et al. Cholinergic neurotransmission in human corpus cavernosum. I. Response of isolated tissue. Am J Physiol. 1988; 254(3 Pt 2):H459-H467.
5. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
6. Ballard SA, Burslem MG, Gingell JC, et al. In vitro profile of UK-92,480 for the treatment of male erectile dysfunction. J Urol. 1996;155:676A.
7. Carter AJ, Ballard SA, Naylor AM. Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile dsyfunction in the anesthetized dog. J Urol. 1998;160:242-246.
8. Hedlund H, Andersson KE. Comparison of the responses to drugs acting on adrenoreceptors and muscarinic receptors in human isolated corpus cavernosum and cavernous artery. J Auton Pharmacol. 1985;5:81-88.
9. Azadzoi KM, Kim N, Brown ML, Goldstein I, Cohen RA, Saenz de Tejada I. Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J Urol. 1992;147:220-225.
10. Knispel HH, Goessl C, Beckmann R. Basal and acetylcholine-stimulated nitric oxide formation mediates relaxation of rabbit cavernous smooth muscle. J Urol. 1991; 146:1429-1433.
11. Naylor AM. Endogenous neurotransmitters mediating penile erection. Br J Urol. 1998;81:424-431.
12. Argiolas A, Melis MR. Neuromodulation of penile erection: an overview of the role of neurotransmitters and neuropeptides. Prog Neurobiol. 1995;47:235-255.
13. Willis EA, Ottesen B, Wagner G, Sundler F, Fahrenkrug J. Vasoactive intestinal polypeptide (VIP) as a putative neurotransmitter in penile erection. Life Sci. 1983;33:383-391.
14. Steers WD, McConnell J, Benson GS. Anatomical localization and some pharmacological effects of vasoactive intestinal polypeptide in human and monkey corpus cavernosum. J Urol. 1984;132:1048-1053.
15. Hedlund H, Andersson KE. Effects of some peptides on isolated human penile erectile tissue and cavernous artery. Acta Physiol Scand. 1985;124:413-419.
16. Adaikan PG, Kottegoda SR, Ratnam SS. Is vasoactive intestinal polypeptide the principal transmitter involved in human penile erection? J Urol. 1986;135:638-640.
17. Wagner G, Gerstenberg T. Intracavernous injection of vasoactive intestinal polypeptide (VIP does not produce erection in man per se). World J Urol. 1987;5:171-177.
18. Kiely EA, Bloom SR, Williams G. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents. Br J Urol. 1989;64:191-194.
19. Roy JB, Petrone RL, Said SI. A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection. J Urol. 1990;143:302-304.
20. Gerstenberg TC, Metz P, Ottesen B, Fahrenkrug J. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol. 1992;147:1277-1279.
21. Stackl W, Hasun R, Marberger M. Intracavernous injection of prostaglandin E1 in impotent men. J Urol. 1988;140:66-68.
22. Ishii N, Watanabe H, Irisawa C, et al. Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J Urol. 1989;141:323-325.
23. Gerber GS, Levine LA. Pharmacological erection program using prostaglandin E1. J Urol. 1991;146:786-789.
24. Ayan S, Yildirim S, Ucar C, Sarioglu Y, Gultekin Y, Butuner C. Corporal reactivity to adenosine and prostaglandin E1 in alloxan-induced diabetic rabbit corpus cavernosum, and the effect of insulin therapy. BJU Int. 1999;83:108-112.
25. Christ GJ, Maayani S, Valcic M, Melman A. Pharmacologic studies of human erectile tissue: characteristics of spontaneous contractions and alterations in alpha-adrenoceptor responsiveness with age and disease in isolated tissues. Br J Pharmacol. 1990;101:375-381.
26. Moreland RB, Traish A, McMillin MA, Smith B, Goldstein I, Saenz de Tejada I. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle. J Urol. 1995;153(3 Pt 1):826-834.
27. Saenz de Tejada I, Kim N, Lagan I, Krane RJ, Goldstein I. Regulation of adrenergic activity in penile corpus cavernosum. J Urol. 1989;142:1117-1121.
28. Diederichs W, Stief CG, Lue TF, Tanagho EA. Norepinephrine involvement in penile detumescence. J Urol. 1990;143:1264-1266.
29. Wahlestedt C, Reis DJ. Neuropeptide Y-related peptides and their receptors - are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol. 1993;33: 309-352.
30. Danjou P, Alexandre L, Warot D, Lacomblez L, Puech AJ. Assessment of erectogenic properties of apomorphine and yohimbine in man. Br J Clin Pharmacol. 1988;26: 733-739.
31. Melis MR, Stancampiano R, Gessa GL, Argiolas A. Prevention by morphine of apomorphine- and oxytocin-induced penile erection and yawning: site of action in the brain. Neuropsychopharmacology. 1992;6:17-21.
32. Morales A, Condra M, Owen JA, Surridge DH, Fenemore J, Harris C. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol. 1987;137:1168-1172.
33. Susset JG, Tessier CF, Wincze J, Bansal S, Malhotra C, Schwacha MG. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol. 1989; 141:1360-1363.
34. Clark JT, Smith ER, Davidson JM. Evidence for the modulation of sexual behavior by alpha-adrenoceptors in male rats. Neuroendocrinology. 1985;41:36-43.
35. DeGroat WC, Booth AM. Neural control of penile erection. In: Maggi CA, ed. The Autonomic Nervous System: Nervous Control of the Urogenital System. London: Harwood, 1993: 465-513.
36. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191-236.
37. Bagdy G, Kalogeras KT, Szemeredi K. Effect of 5-HT1C and 5-HT2 receptor stimulation on excessive grooming, penile erection and plasma oxytocin concentrations. Eur J Pharmacol. 1992;229:9-14.
38. Vincent SR, Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience. 1992;46:755-784.
39. Melis MR, Argiolas A. Nitric oxide synthase inhibitors prevent apomorphine- and oxytocin-induced penile erection and yawning in male rats. Brain Res Bull. 1993;32: 71-74.
40. Abelson D. Diagnostic value of the penile pulse and blood pressure: a Doppler study of impotence in diabetics. J Urol. 1975;113:636-639.
41. Ruzbarsky V, Michal V. Morphologic changes in the arterial bed of the penis with aging: relationship to the pathogenesis of impotence. Invest Urol. 1977;15:194-199.
42. Tesfamariam B, Jakubowski JA, Cohen RA. Contraction of diabetic rabbit aorta caused by endothelium-derived PGH2-TxA2. Am J Physiol. 1989;257(5 Pt 2):H1327-H1333.
43. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990; 323:22-27.
44. Azadzoi KM, Saenz de Tejada I. Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol. 1991;146:238-240.
45. Fani K, Lundin AP, Beyer MM, Jimenez FA, Friedman EA. Pathology of the penis in long-term diabetic rats. Diabetologia. 1983;25:424-428.
46. Faerman I, Glocer L, Fox D, Jadzinsky MN, Rapaport M. Impotence and diabetes: histological studies of the autonomic nervous fibers of the corpora cavernosa in impotent diabetic males. Diabetes. 1974;23:971-976.
47. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia. 1980;18:279-283.
48. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med. 1989;320:1025-1030.
49. Tooke JE, Goh KL. Endotheliopathy precedes type 2 diabetes. Diabetes Care. 1998;21:2047-2049.
50. Tong P, Thomas T, Berrish T, et al. Cell membrane dynamics and insulin resistance in non-insulin-dependent diabetes mellitus. Lancet. 1995;345:357-358.
51. Tribe RM, Poston L. Oxidative stress and lipids in diabetes: a role in endothelium vasodilator dysfunction? Vasc Med. 1996;1:195-206.
52. Jiang ZY, Lin YW, Clemont A, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 1999;104:447-457.
53. Shindo H, Thomas TP, Larkin DD, et al. Modulation of basal nitric oxide-dependent cyclic-GMP production by ambient glucose, myo-inositol, and protein kinase C in SH-SY5Y human neuroblastoma cells. J Clin Invest. 1996;97:736-745.
54. Seftel AD, Vaziri ND, Ni Z, et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology. 1997;50:1016-1026.
55. Crowe R, Lincoln J, Blacklay PF, Pryor JP, Lumley JS, Burnstock G. Vasoactive intestinal polypeptide-like immunoreactive nerves in diabetic penis: a comparison between streptozotocin-treated rats and man. Diabetes. 1983;32:1075-1077.
56. Lincoln J, Crowe R, Blacklay PF, Pryor JP, Lumley JS, Burnstock G. Changes in the VIPergic, cholinergic and adrenergic innervation of human penile tissue in diabetic and non-diabetic impotent males. J Urol. 1987;137: 1053-1059.
57. Christ GJ, Lerner SE, Kim DC, Melman A. Endothelin-1 as a putative modulator of erectile dysfunction, I: characteristics of contraction of isolated corporal tissue strips. J Urol. 1995;153:1998-2003.
58. Francavilla S, Properzi G, Bellini C, Marino G, Ferri C, Santucci A. Endothelin-1 in diabetic and nondiabetic men with erectile dysfunction. J Urol. 1997;158:1770-1774.
59. Tarquini B, Perfetto F, Tarquini R, Cornelissen G, Halberg F. Endothelin-1's chronome indicates diabetic and vascular disease chronorisk. Peptides. 1997;18:119-132.
60. Christ GJ. Gap junctions and ion channels: relevance to erectile dysfunction. Int J Impot Res. 2000;12(Suppl 4): S15-S25.
61. Bacon CG, Hu F, Glasser DB, Mittleman MA, Rimm EB. Duration of diabetes and risk of erectile dysfunction among older men. Diabetes. 2001;50(Suppl 2):A456.
62. Hirsch IB, Korenman SG, Stecher V, Diuguid C. Viagra (sildenafil citrate): efficacy and safety in the treatment of erectile dysfunction (ED) in men with diabetes. Diabetes. 1999;48(Suppl):A55.
63. Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates, P, Boolell M. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med. 1998;15:821-825.
64. Rendell MS, Rajfer J, Wicker PA, Smith MD (Sildenafil Study Group). Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA. 1999;281:421-426.
65. Lewis R, Bennet CJ, Borkon WD, et al. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology. 2001;57: 960-965.
66. Blonde L, Feiner C, Siegel R. Partners' evaluation of the efficacy of Viagra (sildenafil citrate) for the treatment of erectile dysfunction in men with diabetes. Diabetes. 1999; 48(Suppl):A89.
67. Price DE. Erectile dysfunction in patients with diabetes: meta-analysis of 9 sildenafil (Viagra) studies. Diabetologia. 1998;41(Suppl 1):A51.
68. Murphy L, Stuckey B, Jadzinsky MN, Montorsi F, Kadioglu A. Efficacy of sildenafil citrate for erectile dysfunction in men with type 1 diabetes. Diabetes. 2001;50 (Suppl 2):A99.
69. Blonde L, Wohlhuter C, Siegel R, Orazem J. Sildenafil citrate for the treatment of erectile dysfunction in men with diabetes mellitus: stratification by glycemic control. Diabetes. 2001;50(Suppl 2):A90.
70. Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia. 2001;44:1296-1301.
71. Korenman SG, Siegel RL, Stecher VJ, Orazem J. Efficacy of sildenafil citrate in men with erectile dysfunction and diabetes mellitus: effect of patient age and disease duration. Presented at: 83rd Annual Meeting of the Endocrine Society; June 20-23, 2001; Denver, CO.
72. Korenman SG, Wohlhuter C, Sweeney M, Tseng L. Sildenafil citrate for the treatment of erectile dysfunction in men with diabetes mellitus: stratification by diabetic complications. Presented at: 83rd Annual Meeting of the Endocrine Society; June 20-23, 2001; Denver, CO.
73. Hymbaugh M, Blonde L, Wohlhuter C, Siegel R, Orazem J. Efficacy of sildenafil citrate in men with diabetes who have concomitant cardiovascular disease risk factors. Diabetes. 2001;50(Suppl 2):A95.
74. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors [erratum in J Androl. 2002;23:113]. J Androl. 2001;22:793-797.
75. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (Sildenafil Study Group). Oral sildenafil in the treatment of erectile dysfunction [erratum in N Engl J Med. 1998;339:59]. N Engl J Med. 1998;338: 1397-1404.
76. Padma-Nathan H, Steers WD, Wicker PA (Sildenafil Study Group). Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract. 1998;52: 375-379.
77. Virag R. Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology. 1999;54:1073-1077.
78. McMahon CG, Samali R, Johnson H. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J Urol. 2000;164:1192-1196.
79. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol. 1999;162(3 Pt 1):722-725.
80. Goldstein I, Young J, Fischer J, et al. Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function in patients with diabetes mellitus. Diabetes. 2001; 50(Suppl 2):A114.
81. Saenz de Tejada I, Fredlund P, Anglin G, Pullman B, Emmick J. Cialis (IC351) as a treatment of erectile dysfunction in diabetic men. Diabetes. 2001;50(Suppl 2):A425.
82. Saenz de Tejada, I, Emmick J, Anglin G, Fredlund P, Pullman W. The effect of as-needed IC351 treatment of erectile function in men with diabetes. Eur Urol. 2001;39(Suppl 5):16.
83. Chen KK, Chan JY, Chang LS. Dopaminergic neuro-transmission at the paraventricular nucleus of hypothalamus in central regulation of penile erection in the rat. J Urol. 1999;162:237-242.
84. Riley AJ, Goodman RE, Kellett JM, Orr R. Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sexual Marital Ther. 1989;4:17-26.
85. Saenz de Tejada I, Ware JC, Blanco R, et al. Pathophysiology of prolonged penile erection associated with trazodone use. J Urol. 1991;145:60-64.
86. Meinhardt W, Schmitz PI, Kropman RF, de la Fuente RB, Lycklama a Nijeholt AA, Zwartendijk J. Trazodone, a double blind trial for treatment of erectile dysfunction. Int J Impot Res. 1997;9:163-165.
87. Morales A, Heaton JP, Johnston B, Adams M. Oral and topical treatment of erectile dysfunction: present and future. Urol Clin North Am. 1995;22:879-886.
88. Marquer C, Bressolle F. Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence. Fundam Clin Pharmacol. 1998;12:377-387.
89. Willke RJ, Hass SL, Borg G. Intracavernosal alprostadil therapy for diabetics: quality of life results from a clinical trial in Europe and South Africa. Int J Impot Res. 1998; 10(Suppl 3):S14.
90. Shabsigh R, Padma-Nathan H, Gittleman M, McMurray J, Kaufman J, Goldstein I. Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology. 2000;55:477-480.
91. Sandhu D, Curless E, Dean J, et al. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res. 1999;11:91-97.
92. Govier FE, McClure RD, Weissman RM, Gibbons RP, Pritchett TR, Kramer-Levien D. Experience with triple-drug therapy in pharmacological erection program. J Urol. 1993;150:1822-1824.
93. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al (Medicated Urethral System for Erection [MUSE] Study Group). Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med. 1997; 336:1-7.
94. Flynn TN, Guest JF. Intracorporeal and transurethral application of alprostadil: a review of the literature. Int J Impot Res. 1998;10(Suppl 3):S47. Abstract 353.
95. Teloken C, Da Ros C, Sogari P, Palka M, Souto C. Response and adherence to treatment with intraurethral alprostadil (MUSE) in organic erectile dysfunction. Int J Impot Res. 1998;10(Suppl 3):S62. Abstract 457.
96. Goldstein I, Payton TR, Schechter PJ. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) in the in-office treatment of erectile dysfunction. Urology. 2001; 57:301-305.
97. Williams J, Sparkuhl A. Safety and efficacy of lyophilized liposomal prostaglandin E1 (LLPGE1) in patients with erectile dysfunction. Int J Impot Res. 1998; 10(Suppl 3):S64. Abstract 467.
98. Mydlo JH, Volpe MA, Macchia RJ. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol. 2000;38:30-34.
99. Ho LV, Wang R, Mode D, Trap JD, Lewis RW. Viagra and VCD. Int J Impot Res. 1999;11(Suppl 1):S85. Abstract C10.
100. Wang HZ, Lee SW, Christ GJ. Comparative studies of the maxi-K (K(Ca)) channel in freshly isolated myocytes of human and rat corpora. Int J Impot Res. 2000;12:9-18.
101. Benevides MD, Parivar K, Vick RN, et al. Intracavernosal (IC) injection of a potassium channel opener to treat erectile dysfunction. J Urol. 1999; 161(Suppl):212. Abstract 812.
102. Christ GJ, Rehman J, Day N, et al. Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function. Am J Physiol. 1998; 275(2 Pt 2):H600-H608.
103. Bivalacqua TJ, Champion HC, Mehta YS, et al. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int J Impot Res. 2000;12(Suppl 3):S8-S17.
104. Burchardt T, Burchardt M, Chen MW, et al. Expression of VEGF splice variants 144/145 and 205/206 in adult male tissues. IUBMB Life. 1999;48:405-408.
105. Henry GD, Byrne R, Huynh TT, et al. Intracavernosal injections of vascular endothelial growth factor protects endothelial dependent corporal cavernosa smooth muscle relaxation in hypercholesterolemic rabbits: a preliminary study. Int J Impot Res. 2000;12:334-339.
106. Byrne RR, Henry GD, Rao DS, et al. Vascular endothelial growth factor restores corporeal smooth muscle function in vitro. J Urol. 2001;165:1310-1315.
107. Ganz MB, Seftel A. Glucose-induced changes in protein kinase C and nitric oxide are prevented by vitamin E. Am J Physiol Endocrinol Metab. 2000;278:E146-E152.
108. Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000;163:788-791.
109. Guay AT. Efficacy of sildenafil citrate after treatment of reversible causes of erectile dysfunction (ED). Presented at: 23rd Annual Meeting of the Society of General Internal Medicine; May 4-6, 2000; Boston, MA.
110. Quadri R, Zanone M, Maule S, Ponzani P, Fonzo D. Is it possible to prevent andrological complications in the diabetic patient [article in Italian]? Arch Ital Urol Nefrol Androl. 1991;63:435-439.
111. McVary KT, Carrier S, Wessells H (Subcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North America). Smoking and erectile dysfunction: evidence-based analysis. J Urol. 2001;166:1624-1632.